ESC 365 - Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial

ESC Premium Access

Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial

Session: Lipids / Cardiovascular risk prediction / Life style

Topic: Drug therapy

Speaker: Doctor D. Kallend (Zurich, CH)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor David Kallend

The Medicines Company, Zurich (Switzerland)

1 presentation

1 follower

9 more presentations in this session

Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.

Speaker: Ms B. Heidemann (Utrecht, NL)

The contribution of familial hypercholesterolemia (FH) to premature coronary artery disease decreased by 2-fold between 1998 and 2018 in a founder population with high prevalence of FH

Speaker: Doctor A. Lauziere (Chicoutimi, CA)

The effects of climate and air pollutants on heart failure hospitalizations and mortality (CLIMATE-HF Study)

Speaker: Doctor W. Ngampongpan (Bangkok, TH)

Association between secondhand smoke exposure and diabetes mellitus in 131,724 Korean never smokers using self-reported questionnaire and cotinine: gender differences

Speaker: Doctor J. Kim (Seoul, KR)

Irregular eating behavior and incidence of cardiovascular disease: results from a swedish 60-year-old cohort of men and women.

Speaker: Doctor F. Laguzzi (Stockholm, SE)

Access the full session

Lipids / Cardiovascular risk prediction / Life style

Speakers: Doctor D. Kallend, Ms B. Heidemann, Doctor A. Lauziere, Doctor W. Ngampongpan, Doctor J. Kim...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources